Pharmacodynamics of current and emerging PD-1 and PD-L1 inhibitors for the treatment of non-small cell lung cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Pharmacodynamics of current and emerging PD-1 and PD-L1 inhibitors for the treatment of non-small cell lung cancer

Published:2020-01-30 Issue:2 Volume:16 Page:87-96
ISSN:1742-5255
Container-title:Expert Opinion on Drug Metabolism & Toxicology
language:en
Short-container-title:Expert Opinion on Drug Metabolism & Toxicology

Author:

Rocco Danilo¹,Malapelle Umberto²,Del Re Marzia³,Della Gravara Luigi⁴,Pepe Francesco²,Danesi Romano³,Troncone Giancarlo²,Gridelli Cesare⁵

Affiliation:

1. Department of Pulmonary Oncology, AORN Dei Colli Monaldi, Naples, Italy

2. Department of Public Health, Università Degli Studi Di Napoli Federico II, Naples, Italy

3. Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy

4. Department of Experimental Medicine, Università Degli Studi Della Campania Luigi Vanvitelli, Caserta, Italy

5. Division of Medical Oncology, “S.G. Moscati” Hospital, Avellino, Italy

Publisher

Informa UK Limited

Subject

Pharmacology,Toxicology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/17425255.2020.1721460

Reference64 articles.

1. The epidemiology of lung cancer

2.

Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades

3. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

4. Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations

5. PD-1/PD-L1 checkpoint blockades in non-small cell lung cancer: New development and challenges

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mitochondria of T Lymphocytes Promote Anti-Pulmonary Tumor Immune Response;World Journal of Oncology;2024-06

2. Biomarker expression and survival in patients with non-small cell lung cancer receiving adjuvant chemotherapy in Denmark;PLOS ONE;2023-04-11

3. High Expression of TACC3 Is Associated with the Poor Prognosis and Immune Infiltration in Lung Adenocarcinoma Patients;Disease Markers;2022-07-09

4. Programmed Cell Death Protein-1 Inhibitors Versus Programmed Death-Ligand 1 Inhibitors in Addition to Chemotherapy for the First-Line Treatment of Advanced NSCLC: A Systematic Review and Meta-Analysis;JTO Clinical and Research Reports;2021-09

5. Immune checkpoint inhibitors: a new landscape for extensive stage small cell lung cancer treatment;Expert Review of Respiratory Medicine;2021-08-23

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3